19 May 2020
UK-headquartered AstraZeneca is in discussions with international governments and organisations for Covid-19 vaccine candidate manufacturing deals similar to its agreement with the UK government, according to Reuters. The organisations in question are said to include the Coalition for Epidemic Preparedness Innovations (CEPI) and the Global Alliance for Vaccines and Immunisation (Gavi, the Vaccine Alliance).
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
India-based Cipla has plans to explore the use of multi-drug combination, including Gilead Sciences‘ remdesivir, for the treatment of Covid-19. In an interview with Livemint news agency, Cipla chief financial officer Kedar Upadhye said that the company intends to assess a combination of zinc, hydroxychloroquine, azithromycin, lopinavir-ritonavir and favipiravir, among other drugs.
Johnson & Johnson (J&J) has signed an agreement with contract development and manufacturing organisation (CDMO) Vibalogics for the manufacture of clinical trial material for a Covid-19 vaccine candidate being developed by J&J unit Janssen. The deal will see Vibalogics produce multiple batches of the vaccine candidate at its facility in Cuxhaven, Germany.
The European Union may fast track authorisation for the sale of Gilead‘s remdesivir as a potential Covid-19 treatment, said Reuter citing the European Medicines Agency (EMA) head. A conditional approval for the drug is expected in the coming days. The EMA has already called for the compassionate use of the drug for Covid-19 patients
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
